TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 36.85

Change

+2.22 (+6.41)%

Market Cap

USD 1.22B

Volume

0.68M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing TARS

SLX VanEck Steel ETF 4.48 % 0.56 %

-1.15 (-1.45%)

USD 0.10B
BBP Virtus LifeSci Biotech Pr.. 3.26 % 0.79 %

-0.77 (-1.45%)

USD 0.02B
XMHQ Invesco S&P MidCap Qualit.. 2.65 % 0.25 %

-1.87 (-1.45%)

USD 4.71B
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.23 % 0.15 %

-1.22 (-1.45%)

USD 2.45B
IVOG Vanguard S&P Mid-Cap 400 .. 1.21 % 0.20 %

-1.62 (-1.45%)

USD 1.02B
QVMM Invesco Exchange-Traded F.. 0.71 % 0.00 %

-0.39 (-1.45%)

USD 0.30B
DEUS Xtrackers Russell US Mult.. 0.70 % 0.18 %

-0.37 (-1.45%)

USD 0.15B
SPY4:LSE SSgA SPDR ETFs Europe I P.. 0.65 % 0.00 %

-1.02 (-1.45%)

USD 1.93B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.65 % 0.00 %

-0.46 (-1.45%)

USD 1.97B
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.65 % 0.00 %

-0.77 (-1.45%)

USD 1.99B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.65 % 0.00 %

-0.55 (-1.45%)

USD 1.99B
ZMID:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

-0.81 (-1.45%)

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

N/A

N/A
IVOO Vanguard S&P Mid-Cap 400 .. 0.63 % 0.15 %

-1.13 (-1.45%)

USD 1.98B
BKMC BNY Mellon US Mid Cap Cor.. 0.52 % 0.00 %

-1.22 (-1.45%)

USD 0.46B
MVV ProShares Ultra MidCap400 0.50 % 0.95 %

-1.67 (-1.45%)

USD 0.14B
UMDD ProShares UltraPro MidCap.. 0.45 % 0.95 %

-1.07 (-1.45%)

USD 0.03B
MIDU Direxion Daily Mid Cap Bu.. 0.43 % 1.10 %

-1.73 (-1.45%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 81.98% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.98% 88% B+ 94% A
Trailing 12 Months  
Capital Gain 140.07% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.07% 93% A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.54% 58% F 44% F
Dividend Return -0.54% 57% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.13% 58% F 35% F
Risk Adjusted Return -1.13% 57% F 40% F
Market Capitalization 1.22B 84% B 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector